Erythropoietin Does Not Alter Serum Profiles of Neuronal and Axonal Biomarkers After Traumatic Brain Injury: Findings From the Australian EPO-TBI Clinical Trial
Sarah C Hellewell, Stefania Mondello, Alison Conquest, Gerry Shaw, Irina Madorsky, Jay V Deng, Lorraine Little, Firas Kobeissy, Nicole Bye, Rinaldo Bellomo, David J Cooper, Shirley Vallance, Jasmine Board, Maria C Morganti-Kossmann
Critical Care Medicine | LIPPINCOTT WILLIAMS & WILKINS | Published : 2018
Dr. Hellewell was supported by a Centre of Excellence in Traumatic Brain Injury Research (CETBIR) Postdoctoral Fellowship.Drs. Little and Cooper's institutions received funding from National Health and Medical Research Council (NHMRC) Australia. Dr. Little's institution received funding from the Transport Accident Commission (TAC), and she disclosed that she project-managed the EPO-TBI RCT and received a salary via Monash University from the NHMRC and TAC grants for her work. Drs. Bellomo and Cooper disclosed off-label product use of erythropoietin in traumatic brain injury. Dr. Cooper's institution received funding from Victorian Neurotrauma Initiative. The remaining authors have disclosed that they do not have any potential conflicts of interest.